Blackmores Limited operates in the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Blackmores Limited with three other
pharmaceutical manufacturers in Australasia:
Immuron Limited
(2019
sales of 2.92 million Australian Dollars [US$1.74 million]
of which 82%
was HyperImmune Products),
Orthocell Ltd
(956,472.00 Australian Dollars [US$570,009.49 ]
), and
TBG Diagnostics Ltd
(3.44 million Australian Dollars [US$2.05 million]
).
Sales Analysis.
Blackmores Limited reported sales of A$609.50 million (US$363.23 million)
for the
fiscal
year ending
June of 2019.
This
represents
a very small
increase of 1.4%
versus 2018, when the company's sales were A$601.14 million.